Global Market for Cell-Based Assays: Double-Digit Growth to 2023

November 30, 2018

WELLESLEY, Mass., Nov 30,2018 – Growth of the global cell-based assay market is driven by investments in drug discovery and development. With the development of specialized and improved products that provide a greater understanding of cell mechanisms, the market is set to expand. An updated BCC Research study expects this market to reach $32.7 billion by 2023.

Cell-based assays track changes in living cells in response to a wide variety of external stimuli, signals and events. These include receptor activation, stress, drugs, chemicals, changes in the environment and modulated gene and protein expression. The market for cell-based assays and their applications is growing rapidly. From $20.1 billion in 2018, a 5-year compound annual growth rate (CAGR) of 10.2% is projected, according to BCC Research’s newly updated report, Cell-Based Assays: Technologies and Global Markets.

Cell-based assays, which are used in academia and in pharmaceutical R&D, form an integral part of preclinical drug development. These assays facilitate the link between the laboratory and the clinic by identifying adverse effects, addressing safety issues and validating the right candidates for further characterization.

Research Highlights

  • Cell-based assays for the validation of drug targets and lead profiling dominate the 2018 market. At a 10.4% CAGR, this segment is projected to attain $23.6 billion in 2023.
  • The use of cell-based assays in basic research to understand cell signaling and function is the fastest-growing segment, forecast to expand at a 12.1% CAGR over the next 5 years.
  • Cell-based assays offer flexibility and cost advantages over in vivo methods. Advances in automation and high-throughput techniques offer support to this market.

“Technology improvements, high-throughput screening systems, high-content screening and imaging are critical elements of the cell-based assay market,” said BCC Research analyst Sathya Durga. “By using bioassays in automated systems, it is possible to characterize a large number of drug targets and candidates, which makes the drug discovery process efficient and reliable.”

Opportunities/Restraints in the Cell-Based Assay Market

Initially, the market was projected to grow rapidly with the increase in chronic diseases, technological advances and government-supported bans on animal testing in Europe. Now, slower and steadier growth is expected over the 5-year forecast period due to technological challenges and the lack of in vitro models to detect immunostimulation and autoimmunity.

Editors/reporters requesting analyst interviews should contact Eric Surber at

Cell-based Assays: Technologies and Global Markets( BIO080D )
Publish Date: Nov 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.